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Congenital lactase deﬁciency (CLD) is a severe gastrointestinal disorder characterized by watery diarrhea in infants
fed with breast milk or other lactose-containing formulas. We initially assigned the CLD locus by linkage and
linkage disequilibrium on 2q21 in 19 Finnish families. Here we report the molecular background of CLD via
characterization of ﬁve distinct mutations in the coding region of the lactase (LCT) gene. Twenty-seven patients
out of 32 (84%) were homozygous for a nonsense mutation, c.4170TrA (Y1390X), designated “Finmajor.” Four
rare mutations—two that result in a predicted frameshift and early truncation at S1666fsX1722 and S218fsX224
and two point mutations that result in substitutions Q268H and G1363S of the 1,927-aa polypeptide—conﬁrmed
the lactase mutations as causative for CLD. These ﬁndings facilitate genetic testing in clinical practice and enable
genetic counseling for this severe disease. Further, our data demonstrate that, in contrast to common adult-type
hypolactasia (lactose intolerance) caused by a variant of the regulatory element, the severe infancy form represents
the outcome of mutations affecting the structure of the protein inactivating the enzyme.
Received October 19, 2005; accepted for publication November 22, 2005; electronically published December 15, 2005.
Address for correspondence and reprints: Dr. Irma Ja¨rvela¨, Helsinki University Central Hospital, Laboratory of Molecular Genetics, Haart-
maninkatu 2, P.O. Box 140, FIN-00290 Helsinki, Finland. E-mail: irma.jarvela@hus.ﬁ
Am. J. Hum. Genet. 2006;78:339–344.  2005 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7802-0015$15.00
Congenital lactase deﬁciency (CLD [MIM 223000]) is
an autosomal, recessively inherited, severe gastrointes-
tinal disorder of infants. Lactase activity in intestinal
mucosa is decreased to 0–10 U/g of protein, leading to
copious watery diarrhea shortly after breast-feeding or
the introduction of lactose-containing formulas. How-
ever, duodenal morphology and the activities of maltase,
sucrase, and isomaltase are normal. The severe osmotic
diarrhea followed by dehydration, acidosis, and weight
loss usually afﬂict sufferers during the ﬁrst days of life.
Despite the symptoms, CLD infants are vigorous and
hungry. When they are on a lactose-free diet, the symp-
toms subside rapidly and the children have normal
growth and psychomotor development (Launiala et al.
1966; Savilahti et al. 1983). CLD has an incidence of
1:60,000 and is one of the 36 rare monogenic disorders
enriched in the Finnish population (Peltonen et al. 1999;
Norio 2003a, 2003b). However, cases have also been
reported elsewhere in the world (Holzel 1967).
In our linkage report, we deﬁned the critical DNA
region for CLD as from D2S314 to D2S2385. These
microsatellites shared haplotypes from both parents in
16 of 19 studied families and gave the highest linkage
disequilibrium (LD) in disease alleles (Ja¨rvela¨ et al.
1998). However, sequence analyses of regional tran-
scripts failed to reveal disease-causing mutations (data
not shown). Importantly, the critical locus position ex-
cluded the LCT (MIM 603202) gene itself. Further, a
published report of the sequence analysis of the LCT
gene in a Finnish CLD patient failed to reveal disease-
causing mutations in the coding region (Poggi and Se-
bastio 1991). However, since no mutations were found
in transcripts on the linkage region, we wanted to con-
ﬁrm the position of the CLD locus with additional mark-
ers providing higher resolution. We genotyped 15 mi-
crosatellite markers covering 5.88 cM on 2q21–2q22 in
24 families with a total of 32 affected children. We were
able to construct 21 different haplotypes in 48 disease
chromosomes. One major haplotype, cen-5-T13910-7-5-
12-9-6-11-4-15-12-9-7-5-4-4-tel, was present in 18 dis-
ease chromosomes, representing the founder haplotype
from which 15 of the remaining 20 different haplotypes
have been derived (ﬁg. 1). Five disease chromosomes,
each of which carried a different haplotype, did not re-
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Figure 1 CLD haplotypes ordered according to each identiﬁed mutation. Patients 14, 16, 17, 27, and 32 are compound heterozygous for
Y1390X and their respective rare mutations. Microsatellite mutation of D2S314 in one patient increased the total number of CLD chromosomes
to 49. Microsatellite markers were searched for and ordered on the basis of genetic maps of the Marshﬁeld Clinic Research Foundation, as
well as the physical map of the UCSC Genome Browser (December 2001 assembly). The Baylor College of Medicine (BCM) Search Launcher
repeat-masker algorithm was used to identify novel microsatellites from clones between D2S314 and D2S2385 (Smith et al. 1996). Finally, 15
microsatellites and C/T13910, a SNP associated with adult-type hypolactasia, were analyzed, covering 5.88 cM of the CLD region. DNA was
extracted by a standard protocol (Vandenplas et al. 1984) from the peripheral blood samples. PCR was performed and the genotypes were
assigned as described elsewhere (Ylisaukko-oja et al. 2004). Haplotypes were constructed using the GENEHUNTER 2.1 program (Kruglyak
et al. 1996). The CLD founder haplotype was generated with the assumption that there were a minimum number of recombinations.
late to the major haplotype. On the basis of information
about shared haplotypes, we concluded that a critical
region would contain the LCT gene, and we proceeded
to perform sequence analysis of this gene. The transcript
map of the critical DNA region for CLD is shown in
ﬁgure 2.
We identiﬁed ﬁve distinct mutations in the LCT gene
in 32 patients from 24 families. Three mutations were
predicted to lead to a premature truncation of lactase,
and two were missense mutations that resulted in amino
acid substitutions (table 1 and ﬁgs. 3 and 4). All the
chromosomes with the major disease haplotype carried
a nonsense mutation, c.4170TrA (Finmajor), resulting
in Y1390X, a premature stop codon in exon 9 predic-
ting the truncation of 537 amino acids. Finmajor was de-
tected in 27 of 32 patients who were homozygous for
the conserved founder haplotype or its modiﬁcation.
A total of 38 parents (5 did not participate) and 14
healthy siblings were found to be carriers of the Finmajor
mutation. Two patients had a deletion of four nucleo-
tides, c.4998_5001delTGAG, in their paternal disease
chromosome in exon 14, leading to a frameshift and a
premature stop codon after 55 altered amino acids
(S1666fsX1722). These patients were compound het-
erozygous for Finmajor and S1666fsX1722. On the basis
of genealogical studies, both of these mutations are
known to originate from central and northern Finland.
The third mutation, c.653_654delCT, is a deletion of
two nucleotides in exon 2, predicting a frameshift change
at codon 218 and protein truncation at codon 224,
S218fsX224. One patient carried this mutation in her
paternal disease chromosome. The fourth mutation is a
c.804GrC transversion at codon 268, leading to an
amino acid substitution of histidine for glutamine,
Q268H, in the last nucleotide of exon 3. One patient
carried this mutation in her maternal disease chromo-
some. The ﬁfth mutation is a c.4087GrA transition re-
sulting in a missense substitution of serine for an un-
charged glycine, G1363S, at codon 1363 in exon 9. One
patient carried this mutation in his maternal disease
chromosome. A healthy sibling of the family also carried
this rare mutation. These patients were compound het-
erozygous for the Finmajor and their respective rare mu-
tations. On the basis of the birthplaces of the great-
grandparents of the patients, mutations three, four, and
ﬁve would be assumed to originate from eastern Finland.
The CLD mutations and the corresponding lactase ac-
tivities measured from duodenal biopsy specimens are
shown in table 1.
Ninety percent (43/48) of the disease chromosomes
www.ajhg.org Kuokkanen et al.: LCT Mutated in Congenital Lactase Deﬁciency 341
Figure 2 Transcript map of the critical DNA region for CLD. The physical map was constructed using public (International Human
Genome Sequencing Consortium) Human Genome Project annotations. Evidence for transcripts and for conserved amino acids was searched
with BLAST against different databases, including the dbEST and Refseq protein databases. Complete sequence annotations were performed
by the NIX program (UK Human Genome Mapping Project Resource Centre) and the UCSC Genome Browser. LCT, minichromosome main-
tenance deﬁcient 6 (MCM6 [MIM 601806]), aspartyl-tRNA synthetase (DARS [MIM 603084]), chemokine receptor type 4 (CXCR4 [MIM
162643]), and KIAA1679 are the known genes in the region (horizontal arrows). The mouse ortholog (BC063250) of human KIAA1679 suggests
that ESTs BX954188 and BX954180 may be related to transcripts of KIAA1679. Microsatellite markers are indicated by vertical arrows. The
centromere is on the left.
Table 1
CLD Mutations in the LCT Gene and Observed Lactase Activities of Duodenal Biopsy Specimens
DNA Mutation Protein Mutation Exon Patient
Mean Lactase
Protein Activity
(U/g of Protein) Genotype
c.4170TrA Y1390X 9 1–13, 15, 18–26, 28–31 2.1 (range 0–7)a Homozygote
c.4998_5001delTGAG S1666fsX1722 14 17, 32 5 (range 3–7) Compound heterozygoteb
c.653_654delCT S218fsX224 2 16 2 Compound heterozygoteb
c.804GrC Q268H 3 27 5 Compound heterozygoteb
c.4087GrA G1363S 9 14 3 Compound heterozygoteb
a Lactase activities of patients 11, 18, 20, 26, and 29 were not available.
b Compound heterozygote for Y1390X.
carried the Finmajor mutation. The carrier frequency of
Finmajor was determined among 556 anonymous blood
donors representing both the early and the later settle-
ment regions of Finland. The highest carrier frequency
of 1:35 (4/140) was seen in a little town, Nilsia¨, in cen-
tral Finland (ﬁg. 5). This particular geographical region
shows an enrichment of ancestors on genealogical stud-
ies (Ja¨rvela¨ et al. 1998). No carriers for other mutations
(S218fsX224, S1666fsX1722, Q268H, and G1363S)
were observed in any regional subpopulation screened.
The nascent lactase polypeptide contains four (I-IV)
conserved structural and functional regions, but after
posttranslational processing only two (III-IV) remain in
the mature lactase enzyme (Mantei et al. 1988). The
polypeptide has two catalytically active sites: phlorizin
hydrolase activity is located in region III and lactase
activity in region IV (Zecca et al. 1998; Arribas et al.
2000). Finmajor, Y1390X, truncates lactase polypeptide
in the beginning of region IV. We employed an allele-
speciﬁc minisequencing method to characterize the po-
tential impact of the mutation at the steady-state tran-
script level of the LCT allele carrying the nucleotide
change resulting in Y1390X (Rasinpera¨ et al. 2005). We
used a duodenal biopsy sample of a patient who was
heterozygous for the nonsense mutation resulting in
Y1390X and heterozygous for C/T13910, the SNP as-
sociated with adult-type hypolactasia (MIM 223100)
(Enattah et al. 2002; Rasinpera¨ et al. 2005). We were
able to determine that the transcript level of the allele
carrying the premature stop codon was at the same level
as the transcript of the C13910 allele, which typically
represents ca 8% of the expressed LCT mRNA (Kuok-
kanen et al. 2003). We expect this to be caused by non-
sense-mediated mRNA decay, a pathwaywhich degrades
mRNA induced by premature termination codons, elim-
inating the production of harmful truncated proteins
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Figure 3 CLD mutations in the LCT gene. A–E, DNA sequence chromatograms of ﬁve identiﬁed CLD mutations. One mutation, Y1390X,
(A) is a homozygote, whereas the rest of the mutations are heterozygotes. The ﬁrst row shows affected sequences and the second row wild-
type sequences. In addition, c.655GrA, a SNP (rs3754689) leading to V219I, is shown in panel E (Boll et al. 1991). PCR was performed using
the genomic DNA-amplifying promoter region, exons, ﬂanking intron sequences, and 3′-UTRs of the LCT gene (primers are available on request).
Sequencing was performed in both directions, and the sequenced products were electrophoresed on an ABI 3730 DNA analyzer (Applied
Biosystems) in accordance with the manufacturer’s instructions and were analyzed using ABI Sequencing Analysis 3.3 (Applied Biosystems) and
Sequencher 4.1 (Gene Godes).
(Maquat 2005). This mechanism has been seen to mod-
ulate human disease phenotypes caused by disease-as-
sociated premature nonsense or frameshift mutations
(Baserga and Benz 1988; Frischmeyer and Dietz 1999;
Inoue et al. 2004). Furthermore, three of our CLD pa-
tients with the Y1390X mutation were included in an
earlier study in which protein patterns of brush-border
fragments were preliminarily examined (Freiburghaus et
al. 1976). CLD patients had a complete or nearly com-
plete absence of brush-border lactase in studied duo-
denal biopsies (Freiburghaus et al. 1976), which is in
good agreement with our result that the mutant Y1390X
LCT allele is down-regulated by nonsense-mediated de-
cay. The second mutation, S1666fsX1722, truncates lac-
tase in the middle of region IV, and the third mutation,
S218fsX224, truncates polypeptide early, at region I. In
theory, these mutant alleles may also be subjected to
nonsense-mediated decay. The fourthmutation,Q268H,
hits region I, substituting the basic histidine for an un-
charged glutamine. Histidine has an imidazole ring that
can be uncharged or positively charged, depending on
its microenvironment. Although Q268H does not affect
the mature enzyme, it may affect the structure of the
lactase a-profragment, which has been demonstrated to
act during lactase-folding processes as an intramolecular
chaperone towards the mature enzyme (Naim et al.
1994; Jacob et al. 2002). The importance of the Q268
residue is also implied by cross-species conservation
from human through chimpanzee, rabbit, cow, rat, and
mouse. The ﬁfth mutation, G1363S, replaces the small-
est amino acid, glycine, with serine, which has a hy-
droxyl group that makes it polar and reactive. The re-
placement of the small glycine by the larger serine may
alter the three-dimensional structure of the polypeptide.
Since the G1363S mutation is located in the mature lac-
tase at the end of region III, near the catalytically active
sites, it may have serious functional consequences. Also,
G1363 is conserved across species. The schematic struc-
ture of lactase polypeptide and the location of the ﬁve
CLD mutations are illustrated in ﬁg. 4.
Opposite to the rare congenital lactase deﬁciency,
adult-type hypolactasia (MIM 223100) is the most com-
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Figure 4 Structure of lactase and the location of the identiﬁed
CLD mutations. The genomic size of the LCT gene is ∼55 kb and is
composed of 17 exons (Boll et al. 1991). The size of messenger RNA
(mRNA) is 6,274 bases, and the primary translation product (prolac-
tase) is 1,927 amino acids. The prolactase contains a cleavable signal
sequence from Met1 to Gly19 that guides the polypeptide to the en-
doplasmic reticulum (von Heijne 1986; Mantei et al. 1988). The region
from Ser20 to Thr1882 consists of four homologous domains (I–IV). The
prolactase is processed by two proteolytic cleavages. The ﬁrst, an in-
tracellular cleavage, occurs between Arg734 and Leu735. The second
cleavage in the intestinal lumen between Arg868 and Ala869 generates
lactasebﬁnal, the mature enzyme (Jacob et al. 1996; Wu¨thrich et al.
1996). The ﬁgure is modiﬁed from Naim (2001).
Figure 5 Carrier frequency of Y1390X in four subpopulations
in the early and later settlement regions of Finland. The carrier fre-
quencies of the CLD mutations were determined from 556 anonymous
blood donors obtained from the Finnish Red Cross Blood Transfusion
Service.
mon enzyme deﬁciency worldwide. It is caused by de-
velopmental down-regulation of lactase activity during
childhood or early adulthood (Sahi 1994). The decline
of lactase activity is a normal physiological phenome-
non; however, the majority of northern Europeans have
the ability to maintain lactase activity and digest lactose
throughout life (lactase persistence). We previously iden-
tiﬁed C/T13910, a variant that is located 13.9 kb up-
stream of the LCT gene and is associated with the adult-
type hypolactasia trait (Enattah et al. 2002). The
down-regulation of lactase activity operates at the tran-
scriptional level. LCT mRNA quantitated by minise-
quencing method showed that the T13910 allele allows
lactase gene expression and maintains lactase activity,
whereas the C13910 allele lets the down-regulation op-
erate normally (Kuokkanen et al. 2003; Rasinpera¨ et al.
2005). The lactase activity in Finns declines at 5–12
years of age (Rasinpera¨ et al. 2004, 2005). It is of interest
that the CLD Finmajor mutation, Y1390X in lactase, was
systematically found here on the background of the lac-
tase-persistent allele, T13910, in Finns. Thus, some CLD
Finmajor carriers with the CT13910 genotype may suffer
from lactose-induced symptoms after down-regulation
of the C13910 allele.
In conclusion, this study conﬁrms that both human
lactase deﬁciencies are related to DNA variants affecting
the LCT gene. Interestingly, the mutations resulting in
the severe congenital form have direct consequences for
the polypeptide leading to nonsense-mediated mRNA
decay in at least 90% of the disease alleles, whereas the
critical nucleotide for the milder adult-type phenotype
represents a distal enhancer regulating the transcript lev-
els in intestinal cells (Kuokkanen et al. 2003; Olds and
Sibley 2003; Troelsen et al. 2003; Rasinpera¨ et al. 2005).
Importantly, our study facilitates direct DNA-based di-
agnosis and carrier identiﬁcation of CLD, which has so
far been based on clinical symptoms supplemented by
lactase activity assays from intestinal biopsy specimens.
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